Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a ...
New agreement enables both companies to fuel a broad and innovative pipeline of 212 Pb-Radio-DARPin candidates, bringing the total number of programs up to ten Expanded partnership highlights the ...
Cancer care has been transformed by comprehensive molecular profiling and targeted therapies—but with improvements in sample ...
Breast cancer pathogenesis is influenced by various molecular and environmental risk factors. It begins through the mutation of oncogenes, tumor suppressor genes, and dysregulation of key cell ...
Molecular Partners and Orano Med expand collaboration to develop ten 212Pb-Radio-DARPin therapy candidates, initiating clinical trials in 2025. Molecular Partners AG and Orano Med have expanded their ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
Examination of post-radiation survey data from the navigator-assisted hypofractionation (NAVAH) phase I trial in African-American prostate cancer patients. Multivariable logistic regression analysis ...
Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results